1 n carcinoma and 24 patients with a secondary ovarian neoplasm.

2 ared between primary and secondary malignant ovarian neoplasms.

3 in BRCA1 confer susceptibility to breast and ovarian neoplasms.

4 interstitial loss defined in both breast and ovarian neoplasms.

5 th broad applicability to pathologies beyond ovarian neoplasms.

6 er Intergroup International Collaboration on Ovarian Neoplasms 7 (ICON7) trial, bevacizumab improved

7 ucing salpingo-oophorectomy, one early-stage ovarian neoplasm and one early-stage fallopian tube neop

8 unction, confer susceptibility to breast and ovarian neoplasms and are thought to be responsible for

9      This study proved that tumor cells from ovarian neoplasms are shed and can be collected via lava

10 s of women who undergo surgery for suspected ovarian neoplasm do not have cancer.

11 hese trials [the International Collaborative Ovarian Neoplasm Group trial (ICON7), the Gynecologic On

12 differentiate between primary and metastatic ovarian neoplasms in the diagnosis and staging of ovaria

13 ain's underlying propensity for DMBA-induced ovarian neoplasms, our studies underscore the specific i

14 thelium and of gonadotropin-binding sites in ovarian neoplasms provide additional evidence supporting

15 imilarly to progression of disease in women, ovarian neoplasms spread i.p., forming ascites, and meta

16 lts of the large International Collaborative Ovarian Neoplasm Study (ICON2) showed no survival differ

17  represent a distinct category of epithelial ovarian neoplasms that have a clinically more favorable

18 e genetic alterations in 108 sporadic serous ovarian neoplasms to elucidate ovarian serous carcinogen

19 ient population (International Collaborative Ovarian Neoplasm Trial 1/European Organization for Resea

20 Treatment of Cancer Adjuvant Chemotherapy in Ovarian Neoplasm Trial) are being discussed with patient